Teladoc Health, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.53B | $2.57B | $2.60B | $2.41B | $2.03B | $1.09B | $553.3M | $417.9M |
| Cost of Revenue | $771.6M | $751.3M | $760.0M | $744.0M | $650.3M | $390.8M | $184.5M | $128.7M |
| Gross Profit | $1.76B | $1.82B | $1.84B | $1.66B | $1.38B | $703.1M | $368.8M | $289.2M |
| Gross Margin | 69.5% | 70.8% | 70.8% | 69.1% | 68.0% | 64.3% | 66.7% | 69.2% |
| Operating Expenses | ||||||||
| Research & Development | $277.9M | $307.3M | $348.5M | $333.6M | $311.9M | $164.9M | $64.6M | $54.4M |
| SG&A Expense | $431.9M | $435.5M | $464.7M | $449.9M | $438.0M | $506.7M | $164.5M | $116.9M |
| Operating Income | $-263.0M | $-1.02B | $-248.6M | $-13.65B | $-265.6M | $-506.4M | $-80.4M | $-70.9M |
| Operating Margin | -10.4% | -39.7% | -9.6% | -567.3% | -13.1% | -46.3% | -14.5% | -17.0% |
| Interest Expense | — | $23.8M | $22.3M | $21.9M | $81.1M | — | — | — |
| Pretax Income | $-235.5M | $-993.7M | $-219.6M | $-13.66B | $-384.7M | $-576.0M | $-109.5M | $-97.0M |
| Income Tax Expense | $-35.2M | $7.6M | $760.0K | $-3.8M | $44.1M | $-90.9M | $-10.6M | $118.0K |
| Net Income | $-200.3M | $-1.00B | $-220.4M | $-13.66B | $-428.8M | $-485.1M | $-98.9M | $-97.1M |
| Net Margin | -7.9% | -39.0% | -8.5% | -567.5% | -21.1% | -44.3% | -17.9% | -23.2% |
| EPS (Basic) | $-1.14 | $-5.87 | $-1.34 | $-84.60 | $-2.73 | $-5.36 | $-1.38 | $-1.47 |
| EPS (Diluted) | $-1.14 | $-5.87 | $-1.34 | $-84.60 | $-2.73 | $-5.36 | $-1.38 | $-1.47 |
| Shares Outstanding (Basic) | 176.2M | 170.6M | 164.6M | 161.5M | 156.9M | 90.5M | 71.8M | 70.5M |
| Shares Outstanding (Diluted) | 176.2M | 170.6M | 164.6M | 161.5M | 156.9M | 90.5M | 71.8M | 70.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |